$KPTI insider trading
Over the last 12 months, Karyopharm Therapeutics insiders reported no purchases and 20 sales totaling $334K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $334K 20 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Abate KristinChief Accounting Officer · O | ▼ Sale | 19 | $2.02 | $38 | -0.1% | — |
| Jul 28, 2026 | Poulton StuartEVP, Chief Development Officer · O | ▼ Sale | 189 | $7.1 | $1K | -0.2% | — |
| Apr 21, 2026 | Rangwala ReshmaEVP & Chief Medical Officer · O | ▼ Sale | 449 | $8.94 | $4K | -0.8% | — |
| Mar 2, 2026 | Abate KristinChief Accounting Officer · O | ▼ Sale | 559 | $9.41 | $5K | -2.5% | — |
| Mar 2, 2026 | Poulton StuartEVP, Chief Development Officer · O | ▼ Sale | 5,101 | $9.41 | $48K | -5.1% | — |
| Mar 2, 2026 | Cheng Sohanya RoshanEVP & Chief Commercial Officer · O | ▼ Sale | 4,604 | $9.41 | $43K | -4.1% | — |
| Mar 2, 2026 | Mano MichaelEVP, CLO&Secretary · O | ▼ Sale | 3,526 | $9.41 | $33K | -3.6% | — |
| Mar 2, 2026 | Rangwala ReshmaEVP & Chief Medical Officer · O | ▼ Sale | 5,066 | $9.41 | $48K | -8.2% | — |
| Mar 2, 2026 | Paulson Richard A.President and CEO · O·D | ▼ Sale | 12,361 | $9.41 | $116K | -4.4% | — |
| Feb 17, 2026 | Poulton StuartEVP, Chief Development Officer · O | ▼ Sale | 378 | $8.63 | $3K | -0.4% | — |
| Feb 3, 2026 | Macomber LoriEVP, CFO & Treasurer · O | ▼ Sale | 1,626 | $6.3 | $10K | -1.9% | — |
| Jan 28, 2026 | Abate KristinChief Accounting Officer · O | ▼ Sale | 50 | $7.03 | $352 | -0.2% | — |
| Jan 21, 2026 | Abate KristinChief Accounting Officer · O | ▼ Sale | 265 | $5.96 | $2K | -1.2% | — |
| Oct 1, 2025 | Abate KristinChief Accounting Officer · O | ▼ Sale | 362 | $6.3 | $2K | -3.5% | — |
| Sep 15, 2025 | Paulson Richard A.President and CEO · O·D | ▼ Sale | 1,257 | $6.43 | $8K | -1.5% | — |
| Sep 15, 2025 | Mano MichaelSVP, General Counsel&Secretary · O | ▼ Sale | 234 | $6.43 | $2K | -1.1% | — |
| Sep 15, 2025 | Poulton StuartEVP, Chief Development Officer · O | ▼ Sale | 401 | $6.43 | $3K | -1.4% | — |
| Sep 15, 2025 | Rangwala ReshmaEVP & Chief Medical Officer · O | ▼ Sale | 408 | $6.43 | $3K | -1.4% | — |
| Sep 15, 2025 | Cheng Sohanya RoshanEVP & Chief Commercial Officer · O | ▼ Sale | 325 | $6.43 | $2K | -0.9% | — |
| Sep 15, 2025 | Abate KristinChief Accounting Officer · O | ▼ Sale | 23 | $6.43 | $148 | -0.2% | — |
| Sep 3, 2025 | Abate KristinChief Accounting Officer · O | ▼ Sale | 12 | $6.78 | $81 | -0.1% | — |
Every $KPTI filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Karyopharm Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KPTI feed.